Silverarc Capital Management, LLC Aclaris Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $6,872 - $9,267	-871 Reduced 0.4%	219,229 $2.27 Million
Q1 2023 May 15, 2023	SELL	$7.07 - $17.95 $933,897 - $2.37 Million	-132,093 Reduced 37.51%	220,100 $1.78 Million
Q4 2022 Feb 14, 2023	SELL	$14.33 - $18.37 $2.75 Million - $3.52 Million	-191,583 Reduced 35.23%	352,193 $5.55 Million
Q3 2022 Oct 28, 2022	BUY	$13.07 - $18.22 $55,299 - $77,088	4,231 Added 0.78%	543,776 $8.56 Million
Q2 2022 Jul 25, 2022	BUY	$10.16 - $17.08 $2.68 Million - $4.51 Million	264,212 Added 95.96%	539,545 $7.53 Million
Q1 2022 May 13, 2022	SELL	$9.74 - $17.92 $106,097 - $195,202	-10,893 Reduced 3.81%	275,333 $4.75 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $1.39 Million - $2.09 Million	112,899 Added 65.14%	286,226 $4.16 Million
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $205,944 - $289,369	-15,392 Reduced 8.16%	173,327 $3.12 Million
Q2 2021 Aug 16, 2021	SELL	$17.08 - $29.6 $2.53 Million - $4.38 Million	-148,018 Reduced 43.96%	188,719 $3.31 Million
Q1 2021 May 18, 2021	BUY	$5.86 - $27.73 $1.97 Million - $9.34 Million	336,737 New	336,737 $8.49 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $255M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.